Meeting
2017 ASCO Annual Meeting
Recurrent versus de novo metastatic NSCLC: Impact on outcomes.
Authors
Sara Moore
BC Cancer Agency, Vancouver, BC, Canada
Sara Moore , Bonnie Leung , Jonn Wu , Aria Shokoohi , Cheryl Ho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9045)
DOI
10.1200/JCO.2017.35.15_suppl.9045
Abstract #
9045
Poster Bd #
371
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
The impact of clinical stage at primary melanoma diagnosis on post-recurrence survival.
First Author: Kierstin Utter
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of exposure to clinical trials and standard-of-care therapy in metastatic or recurrent prostate cancer: An update.
First Author: Grace G Kim
Poster
2023 ASCO Annual Meeting
Role of immunotherapy in stage IV non-small cell lung cancer with liver metastasis: A NCDB analysis.
First Author: Takefumi Komiya
Poster
2023 ASCO Genitourinary Cancers Symposium
Multicenter population-level analysis of systemic therapy use in metastatic or recurrent prostate cancer.
First Author: Heba Mohamed